Genenta Science S.p.A (GNTA) Other Accumulated Expenses (2020 - 2025)
Genenta Science S.p.A (GNTA) posted Other Accumulated Expenses of $138521.2 for Q4 2025, down 50.07% sequentially from $277450.1 in Q2 2025, and down 61.62% YoY from $360933.1 in Q4 2024.
Genenta Science S.p.A (GNTA) Other Accumulated Expenses (2020 - 2025) Analysis & Trends
Genenta Science S.p.A has reported Other Accumulated Expenses for 6 years, with the latest figure at $138521.2 in Q4 2025.
- Quarterly Other Accumulated Expenses fell 61.62% year-over-year to $138521.2 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $138521.2 (down 61.62% YoY) and the FY2025 annual result came in at $138521.2, down 61.62% from the prior year.
- Other Accumulated Expenses declined to $138521.2 in Q4 2025 per GNTA's latest filing, from $277450.1 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $475226.2 in Q2 2024 and troughed at $115219.6 in Q4 2021.
- A 5-year average of $256007.0 and a median of $274431.4 in 2023 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2025: Other Accumulated Expenses jumped 163.76% in 2022, then sank 61.62% in 2025.
- Over 5 years, Other Accumulated Expenses stood at $115219.6 in 2021, then surged by 163.76% to $303906.2 in 2022, then decreased by 9.7% to $274431.4 in 2023, then jumped by 31.52% to $360933.1 in 2024, then tumbled by 61.62% to $138521.2 in 2025.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $138521.2, $277450.1, and $360933.1 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Genenta Science S.p.A | 25.03 Mn | -34.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 138,521.18 |
| Jun 30, 2025 | 277,450.11 |
| Dec 31, 2024 | 360,933.06 |
| Jun 30, 2024 | 475,226.18 |
| Dec 31, 2023 | 274,431.39 |
| Jun 30, 2023 | 230,059.23 |
| Dec 31, 2022 | 303,906.18 |
| Jun 30, 2022 | 128,315.70 |
| Dec 31, 2021 | 115,219.61 |
| Dec 31, 2020 | 63,481.09 |